TY - JOUR T1 - Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection JF - Pharmacological Reviews JO - Pharmacol Rev SP - 358 LP - 403 DO - 10.1124/pr.107.00107 VL - 60 IS - 3 AU - Jeffrey A. Lieberman AU - Frank P. Bymaster AU - Herbert Y. Meltzer AU - Ariel Y. Deutch AU - Gary E. Duncan AU - Christine E. Marx AU - June R. Aprille AU - Donard S. Dwyer AU - Xin-Min Li AU - Sahebarao P. Mahadik AU - Ronald S. Duman AU - Joseph H. Porter AU - Josephine S. Modica-Napolitano AU - Samuel S. Newton AU - John G. Csernansky Y1 - 2008/09/01 UR - http://pharmrev.aspetjournals.org/content/60/3/358.abstract N2 - Various lines of evidence indicate the presence of progressive pathophysiological processes occurring within the brains of patients with schizophrenia. By modulating chemical neurotransmission, antipsychotic drugs may influence a variety of functions regulating neuronal resilience and viability and have the potential for neuroprotection. This article reviews the current literature describing preclinical and clinical studies that evaluate the efficacy of antipsychotic drugs, their mechanism of action and the potential of first- and second-generation antipsychotic drugs to exert effects on cellular processes that may be neuroprotective in schizophrenia. The evidence to date suggests that although all antipsychotic drugs have the ability to reduce psychotic symptoms via D2 receptor antagonism, some antipsychotics may differ in other pharmacological properties and their capacities to mitigate and possibly reverse cellular processes that may underlie the pathophysiology of schizophrenia. ER -